ACST - Acasti Pharma Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Laval,
Canada
Type: Equity
ACST price evolution
ACST
| (in millions $) | 30 Oct 2024 | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $0.96 | $0.8 | $0.84 | |
| Inventory | ||||
| Total current assets | $26.88 | $28.9 | $23.61 | |
| Long term investments | ||||
| Property, plant & equipment | $0.04 | $0.1 | $0.15 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $76.19 | $78.2 | $73.03 | |
| Current liabilities | ||||
| Accounts payable | $1.45 | $1.2 | $1.6 | |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $1.77 | $1.4 | $1.97 | |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $11.51 | $11.5 | $9.02 | |
| Shareholders' equity | ||||
| Retained earnings | -$207.95 | -$205.6 | -$202.29 | |
| Other shareholder equity | -$6.04 | -$6 | -$6.04 | |
| Total shareholder equity | ||||
| (in millions $) | 1 May 2023 | 1 May 2022 | 30 Mar 2021 | 30 Mar 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $30.34 | $50.94 | $14.24 | |
| Short term investments | $13.32 | $9.79 | ||
| Net receivables | $0.8 | $0.55 | $0.53 | $0.55 |
| Inventory | $0.2 | |||
| Total current assets | $29.29 | $45.53 | $62.37 | $16.08 |
| Long term investments | ||||
| Property, plant & equipment | $0.57 | $0.32 | $0.09 | $2.06 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.09 | $4.39 | ||
| Total investments | ||||
| Total assets | $79.12 | $128.62 | $62.46 | $22.85 |
| Current liabilities | ||||
| Accounts payable | $2.19 | $1.68 | $0.12 | $1.71 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $3.41 | $3.26 | $1.58 | $7.39 |
| Long term debt | ||||
| Total noncurrent liabilities | $5.22 | $2.46 | ||
| Total debt | ||||
| Total liabilities | $11.17 | $20.35 | $6.8 | $9.86 |
| Shareholders' equity | ||||
| Retained earnings | -$198.27 | -$155.84 | -$146.02 | -$126.34 |
| Other shareholder equity | -$6.04 | -$6.04 | -$6.33 | -$7.89 |
| Total shareholder equity | $108.27 | $55.66 | $12.99 | |
| (in millions $) | 30 Oct 2024 | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $2.07 | |||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0.45 | |||
| Interest expense | -$1.63 | |||
| Net income | ||||
| Net income | -$3.27 | |||
| Income (for common shares) | ||||
| (in millions $) | 1 May 2023 | 1 May 2022 | 30 Mar 2021 | 30 Mar 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.2 | |||
| Cost of revenue | $0.08 | |||
| Gross Profit | $0.12 | |||
| Operating activities | ||||
| Research & development | $4.17 | $15.97 | ||
| Selling, general & administrative | $6.66 | $8.46 | ||
| Total operating expenses | $18.25 | $12.14 | $10.91 | $24.44 |
| Operating income | -$10.72 | -$24.44 | ||
| Income from continuing operations | ||||
| EBIT | -$10.72 | -$24.44 | ||
| Income tax expense | -$9.54 | -$0.65 | ||
| Interest expense | $0.18 | $3.26 | -$0.25 | |
| Net income | ||||
| Net income | -$42.43 | -$9.82 | -$19.68 | -$25.51 |
| Income (for common shares) | -$19.68 | -$25.51 | ||
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$6.44 | $0.11 | $13.15 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $7.36 | $7.36 | $0.3 | |
| Effect of exchange rate | -$0 | -$0.01 | ||
| Change in cash and equivalents | -$9.33 | -$0.88 | -$6.24 | -$2.46 |
| (in millions $) | 1 May 2023 | 1 May 2022 | 30 Mar 2021 | 30 Mar 2020 |
|---|---|---|---|---|
| Net income | -$19.68 | -$25.51 | ||
| Operating activities | ||||
| Depreciation | $0.92 | $2.32 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$14.32 | -$22.94 | ||
| Investing activities | ||||
| Capital expenditures | -$0.07 | -$0.32 | ||
| Investments | -$9.79 | $8.46 | ||
| Total cash flows from investing | $13.15 | -$3.52 | -$9.86 | $8.14 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$1.56 | |||
| Total cash flows from financing | $0.3 | $59.49 | $13.18 | |
| Effect of exchange rate | -$0.01 | -$0.3 | $1.39 | -$1 |
| Change in cash and equivalents | -$2.46 | -$20.6 | $36.7 | -$2.63 |
News
|
12 Best Biotech Penny Stocks to Invest In
Insider Monkey via Yahoo Finance
24 Mar 2024
|
|
When Will Acasti Pharma Inc. (NASDAQ:ACST) Turn A Profit?
Simply Wall St. via Yahoo Finance
30 Mar 2023
|
|
5 Best Penny Stocks on Robinhood To Invest In for 2023
AOL
3 Feb 2023
|
|
Parsing which foods are healthy and which are less so isn't always straightforward – a new rating...
The Conversation via Yahoo News
20 Jan 2023
|
|
Acasti Pharma's IV Hemorrhage Drug Candidate At Par With Oral Nimodipine
Benzinga via Yahoo Finance
18 May 2022
|
|
10 Biotech Penny Stocks Redditors Love
Insider Monkey via Yahoo Finance
6 May 2022
|
|
Equities Research Analysts’ Updated EPS Estimates for April 19th (ABG, ACST, ADPT, AHH, AME, AVDX,...
ETF DAILY NEWS
19 Apr 2022
|
|
New Strong Sell Stocks for February 23rd
Zacks via Yahoo Finance
23 Feb 2022
|
|
Acasti: Fiscal Q3 Earnings Snapshot
Stamford Advocate
14 Feb 2022
|
|
Acasti: Fiscal Q3 Earnings Snapshot
The News-Times
14 Feb 2022
|
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |